Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

2013102 citationsJournal Article

Authors

Volker Heinemann · Ludwig-Maximilians-Universität München

Ludwig Fischer von Weikersthal · Klinikum St. Marien Amberg

Thomas Decker · Ravensburg University of Cooperative Education

Alexander Kiani · Bayreuth Medical Center

Ursula Vehling‐Kaiser · University of Applied Sciences Landshut

Salah‐Eddin Al‐Batran · Goethe University Frankfurt

Tobias Heintges

Abstract

LBA3506 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Topics & Keywords

Colorectal Cancer Treatments and Studies Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 31, Issue 15_suppl, pp. LBA3506-LBA3506

DOI: 10.1200/jco.2013.31.15_suppl.lba3506

Field-Weighted Citation Impact: 14.33